{"product_id":"quipthomemedical-five-forces-analysis","title":"Quipt Home Medical Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eQuipt Home Medical faces moderate supplier power and strong buyer expectations amid growing home healthcare demand, while regulatory barriers and niche incumbents shape entrant threats.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Quipt Home Medical’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Respiratory Equipment Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe high-end respiratory device market is highly concentrated: ResMed and Philips together held about 60% global CPAP market share in 2024, giving them pricing and supply leverage during demand spikes like winter 2023–24 when lead times doubled.\u003c\/p\u003e\n\u003cp\u003eThat concentration lets suppliers prioritize large OEMs, so Quipt must secure preferred vendor terms and safety-stock; holding 8–12 weeks of inventory cut stockout risk for similar retailers in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical Nature of Proprietary Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of advanced monitoring software and medical hardware exert strong leverage over Quipt Home Medical because proprietary ecosystems raise switching costs—industry data shows platform migration can exceed $1.2m per large deployment and take 6–12 months. As Quipt embeds these systems into its RPM services, vendors can set software-update cadence, licensing fees (often 10–25% of device cost annually), and hardware compatibility rules. This dependency concentrates supplier power and compresses Quipt’s margin flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Global Supply Chain Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpby the end of pandemic-era disruptions largely eased but raw material and logistics costs remain volatile with global freight rates up from levels semiconductor prices higher year-over-year suppliers pass increases to wholesalers. any upward manufacturing cost pressure is typically forwarded providers like quipt home medical squeezing margins because cms private payer reimbursement are relatively inelastic. gross margin risk tangible: a supplier price hike could cut by percentage points given current structure near what this estimate hides: contract terms hedges scale discounts can reduce hit.\u003e\n\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImportance of Specialized Medical Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of specialized consumables (masks, tubing, filters) hold steady bargaining power for Quipt Home Medical because these items are device-specific and essential for patient use; without them patients cannot use the primary equipment, creating locked-in demand. In the U.S. home-medical market, recurring consumables account for roughly 20–30% of device lifecycle spend, so suppliers can deploy tiered pricing and subscription models to capture margin. This raises procurement risk and compresses gross margins unless Quipt secures long-term contracts or vertical integration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsumables are device-specific, creating lock-in\u003c\/li\u003e\n\u003cli\u003eRecurring spend ≈20–30% of lifecycle costs (U.S. home-medical)\u003c\/li\u003e\n\u003cli\u003eSuppliers can use tiered pricing\/subscriptions\u003c\/li\u003e\n\u003cli\u003eMitigations: long-term contracts, multiple suppliers, vertical integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Threat of Forward Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eManufacturers set component prices, but the risk they will vertically integrate into direct-to-patient home medical services is low because local logistics, regulated clinical support, and last-mile delivery add large operational complexity and cost.\u003c\/p\u003e\n\u003cp\u003eMost suppliers favor higher-margin manufacturing: global medtech firms reported 2024 gross margins of 40–55%, so shifting to service-heavy models like Quipt’s would compress margins and require new capabilities.\u003c\/p\u003e\n\u003cp\u003eAs a result, supplier leverage is mainly over price and contract terms, not over market access or customer relationships, limiting their ability to displace Quipt directly.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh supplier gross margins (40–55% in 2024)\u003c\/li\u003e\n\u003cli\u003eLocal last-mile logistics and clinical regs raise entry costs\u003c\/li\u003e\n\u003cli\u003eSuppliers prefer manufacturing over service operations\u003c\/li\u003e\n\u003cli\u003ePrimary supplier power: price negotiation, not substitution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier power risks Quipt margins—5% price hike could shave ~2–3 pts; hedges: contracts, multi-sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate–high power: ResMed\/Philips ~60% CPAP share (2024), consumables =20–30% lifecycle spend, software migration \u0026gt;$1.2m and 6–12 months, supplier gross margins 40–55% (2024). A 5% supplier price rise could cut Quipt gross margin ~2–3 pts given 2024 ~30% gross margin; mitigations: long-term contracts, multi-sourcing, inventory (8–12 weeks).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPAP market share (ResMed+Philips)\u003c\/td\u003e\n\u003ctd\u003e~60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables % lifecycle\u003c\/td\u003e\n\u003ctd\u003e20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware migration cost\/time\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1.2m \/ 6–12m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier gross margin\u003c\/td\u003e\n\u003ctd\u003e40–55% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuipt gross margin\u003c\/td\u003e\n\u003ctd\u003e~30% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Quipt Home Medical, this Porter’s Five Forces analysis uncovers competitive intensity, buyer and supplier power, substitute threats, and entry barriers—identifying disruptive forces and strategic levers that influence pricing, profitability, and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, one-sheet Porter's Five Forces snapshot for Quipt Home Medical—ideal for rapid assessment of competitive pressures and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominance of Government Payers and Reimbursement Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant share of quipt home medicals revenue in fy2024 from medicare and medicaid which hold ultimate bargaining power via fixed fee schedules that cap reimbursements for durable medical equipment.\u003e\n\u003cpthose programs set device prices leaving quipt little ability to negotiate higher rates medicare dme fell in real terms from after competitive bidding expansions.\u003e\n\u003cppolicy shifts like cms competitive bidding rounds or reimbursement rule proposals can cut margins on oxygen concentrators and supplies quickly swinging product-line profitability by double digits.\u003e\n\u003c\/ppolicy\u003e\u003c\/pthose\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Private Insurance Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US private insurance market is highly concentrated: in 2024 the top five payers covered ~60% of enrollees, allowing them to demand lower durable medical equipment (DME) rates and stricter service SLAs from providers like Quipt Home Medical.\u003c\/p\u003e\n\u003cp\u003eThese payers leverage patient volume—millions of lives—to extract favorable contract terms; Quipt faces margin pressure when payers push fee cuts or higher performance penalties.\u003c\/p\u003e\n\u003cp\u003eNetwork exclusion is material: being dropped by a major insurer can remove 30–50% of local demand overnight, sharply reducing revenue and negotiating leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Physician Referral Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn DME, patients have limited bargaining power compared with referring physicians who act as gatekeepers; studies show 65–80% of durable medical equipment referrals follow physician preference (2023 CMS\/industry reports). Physicians pick providers based on service reliability, easy electronic ordering, and outcomes; Quipt must prioritize these metrics—same-day fulfillment rates, 98% claim accuracy, and 30‑day readmission impact—to keep referral pipelines, effectively treating physicians as primary customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Sensitivity to Out of Pocket Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs high-deductible plans rose to 30% of US workers by 2024, patients pay larger co-pays and deductibles for home medical equipment, boosting their price sensitivity and bargaining power versus providers.\u003c\/p\u003e\n\u003cp\u003ePatients now shop providers for lower out-of-pocket costs or financing; surveys show 42% delay durable medical purchases due to cost, forcing Quipt to match price transparency with service quality to keep loyalty.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eRising HDHP prevalence: ~30% of workers (2024)\u003c\/li\u003e\n\u003cli\u003e42% delay purchases due to cost\u003c\/li\u003e\n\u003cli\u003eQuipt must pair cost-transparency with quality\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Transparent Quality Metrics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy late 2025, online reviews and standardized patient-satisfaction scores (e.g., HCAHPS-like metrics) have increased customer power, with 68% of patients consulting ratings before choosing home medical services.\u003c\/p\u003e\n\u003cp\u003ePatients and families can directly compare Quipt Home Medical against local and national competitors via platforms showing net promoter scores and 4.2+ average star ratings nationwide.\u003c\/p\u003e\n\u003cp\u003eThis transparency forces Quipt to boost spending on customer service and clinical support—estimated 5–8% revenue reinvestment—to reduce churn to higher-rated providers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% consult ratings\u003c\/li\u003e\n\u003cli\u003e4.2+ avg star ratings\u003c\/li\u003e\n\u003cli\u003e5–8% revenue spent on service\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuipt squeezed by payers, price-sensitive patients and rising service costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpquipt faces high customer bargaining power: medicare drove of fy2024 revenue and cap dme rates top-5 private insurers covered enrollees in enabling fee pressure patients hdhps online ratings consult them raise price sensitivity churn risk quipt now spends on service to defend margins.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/Medicaid share FY2024\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 insurers enrollee share 2024\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHDHP workers 2024\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients consulting ratings\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService reinvestment\u003c\/td\u003e\n\u003ctd\u003e~5–8% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pquipt\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eQuipt Home Medical Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Quipt Home Medical you'll receive immediately after purchase—no placeholders or mockups, fully formatted and ready for use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746908057977,"sku":"quipthomemedical-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/quipthomemedical-five-forces-analysis.png?v=1772193137","url":"https:\/\/growthsharematrix.com\/products\/quipthomemedical-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}